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MaOBJECTIVES This study sought to evaluate the feasibility of transfemoral transcatheter heart valve (THV) implantation
in failed mitral bioprostheses and ring annuloplasties.
BACKGROUND Redo mitral surgery may be high risk or contraindicated due to comorbidity. THV implantation has been
recently reported in this setting.
METHODS Transfemoral implantation of Edwards Sapien prosthesis was performed in 17 patients for degenerated mitral
bioprosthesis or previous ring annuloplasty (6 bioprostheses, 11 ring annuloplasties). The procedure was elective for
14 patients and attempted as a rescue in 3 patients. Mean age was 61  24 years. All patients were in New York Heart
Association class $III, and the surgical risk was high (EuroSCORE [European System for Cardiac Operative Risk Evalua-
tion]: 37  29%, Society of Thoracic Surgeons score: 18  22%).
RESULTS Procedure was successful in 14 patients (82%). Two complications occurred during rescue procedures:
1 procedural death and 1 THV migration. One patient had moderate paraprosthetic regurgitation following the procedure,
whereas residual regurgitation was trace or less in 11 patients (69%) and mild in 4 patients (25%). Mean gradient
decreased from 12  6 mm Hg to 8  3 mm Hg. During a mean follow-up of 22 months, 4 patients died, 3 from cardiac
cause. The 18-month survival was 68  14% in the overall population and 78  14% for patients with elective procedure.
One patient underwent mitral valve replacement due to periprosthetic mitral regurgitation. At last follow-up, 12 patients
were in New York Heart Association class #II (75%) and 4 in class III (25%).
CONCLUSIONS This single-center series suggests that transfemoral THV implantation for deterioration of mitral bio-
prosthesis or surgical repair is feasible in selected patients and improves early hemodynamic and midterm functional
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ABBR EV I A T I ON S
AND ACRONYMS
BP = bioprosthesis
CT = computed tomography
MVIVI = mitral valve-in-valve
implantation
NYHA = New York Heart
Association
RA = ring annuloplasty
TEE = transesophageal
echocardiography
THV = transcatheter heart
valve
Bouleti et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 , 2 0 1 5
Mitral THV Implantation J A N U A R Y 2 0 1 5 : 8 3 – 9 1
84especially in patients with concurrent
comorbidities (2,3).
Following the ﬁrst description of trans-
catheter heart valve (THV) implantation for
native aortic valve stenosis (4), treatment of
failed aortic BP with THV implantation has
emerged as a promising alternative to redo
surgery in high-risk patients (5,6). Recently,
THV implantation has also been reported for
treatment of failed mitral BP or RA, mainly
through the transapical approach (7–15).
We sought to evaluate the immediate and
midterm results of transfemoral implantation
of balloon-expandable Sapien XT valves(Edwards Lifesciences, Irvine, California) for failed
mitral surgical valves in highly selected patients.METHODS
POPULATION. The population consisted of symp-
tomatic patients who underwent transfemoral im-
plantation of a THV in mitral position for failing BP or
RA at our institution from March 2, 2011 to August 16,
2013. No transapical approaches were performed
during the same period. The decision to perform the
intervention was based on a consensual agreement
between the members of the heart team in patients
considered at high risk for redo surgery. Informed
consent for the procedure was obtained from all
patients.
PROCEDURE. Prosthesis/annulus measurements.
The choice of the THV size was based on an integra-
tive approach taking into account manufacturer’s
inner diameters, and also the mean diameter deter-
mined from the long and short diameter measure-
ments as assessed by computed tomography (CT),
3-dimensional transesophageal echocardiography
(TEE), and ﬂuoroscopy.
THV implantat ion procedures. The technique for
THV implantation in mitral position through a trans-
femoral approach has been described previously
(8,16,17). All procedures were performed under gen-
eral anesthesia and TEE guidance, with the exception
of 1, which was done under local anesthesia and
ﬂuoroscopic guidance due to impossible tracheal
intubation. Bilateral femoral venous access was used.
A temporary pacemaker lead was placed in the right
ventricle as used during transcatheter aortic valve
implantation. Transseptal puncture was performed
under TEE guidance in a “high “and “posterior”
position similar to that used during MitraClip (Abbott
Vascular, Santa Clara, California) implantation. After
placing a Mullins sheath (Medtronic, Minneapolis,Minnesota) in the left atrium, a bolus of heparin
(70 IU/kg) was administered with the aim of achieving
an activated clotting time between 250 and 300 s.
Then the mitral valve was crossed with a Judkins
right 5-F catheter advanced on a standard 0.035-inch
guidewire or a 7-F balloon wedge pressure catheter
(Arrow International, Reading, Pennsylvania). Then,
a 0.035-inch Amplatz Super Stiff or Lunderquist
guidewire (Cook Medical, Bloomington, Indiana) with
a “J” curve at the end was placed in the apex of the
left ventricle (Figure 1A). The atrial septum was
dilated using 12- to 14-mm peripheral balloons.
Although pre-dilation should generally be avoided, it
was performed in 3 cases due to anticipated difﬁ-
culties in crossing highly stenotic bioprostheses. In
addition, 1 procedure was performed immediately
after failed balloon valvuloplasty in a case of reste-
nosis after open-heart commissurotomy with annu-
loplasty. Then the Sapien XT valve, mounted for
antegrade implantation (similar to the position in
transapical aortic valve procedures) on a NovaFlex
catheter (Edwards Lifesciences), was advanced
through the atrial septum. The THV was orientated
toward the mitral valve and positioned using maximal
ﬂexion of the NovaFlex catheter. Implantation was
performed by slow balloon inﬂation under rapid
ventricular pacing (160 to 200 beats/min) (Figure 1B).
Post-dilation was performed in 3 cases of moderate
paravalvular regurgitation. The ﬁnal result of im-
plantation was assessed by echocardiography and
ﬂuoroscopy in the catheterization lab (Figures 1C
and 1D) and CT before discharge (Figures 1E and 1F).
Contrast medium was not used during mitral implan-
tation, except in 1 case for positioning of a cerebral
protection device (Embrella, Edwards Lifesciences)
during mitral valve-in-valve implantation (MVIVI)
within a severely calciﬁed and stenotic BP.
The femoral veins were closed by manual com-
pression or suture.
DEFINITIONS. Complications were reported accord-
ing to the VARC-2 (Valve Academic Research Con-
sortium Procedural) criteria (18). Device success was
deﬁned as the absence of procedural mortality, the
correct positioning of a single THV, and the absence of
residual moderate or severe prosthetic regurgitation.
Prosthetic function was assessed before discharge ac-
cording to current guidelines, using the integration of
qualitative and quantitative parameters obtained by
echocardiography and adapted to prostheses in mitral
position (18–20). THV regurgitation was graded as ab-
sent, trace, mild, moderate, or severe.
FOLLOW-UP. Clinical evaluation and echocardiogra-
phy (transthoracic and transesophageal) were
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85performed before discharge. All adverse events were
prospectively recorded. The 30-day, 6-month, 1-year,
and 2-year medical visits were performed in our
institution or by the patients’ own cardiologist.
Follow-up was complete in all patients. Mean follow-
up was 22  3 months, and maximum follow-up
reached 28 months.
STATISTICAL ANALYSIS. Quantitative variables were
expressed as mean  SD. Qualitative variables were
expressed as percentages. Comparisons of variables
before and after the procedure used the Wilcoxon
signed rank test for quantitative variables. In cases
in which more than 2 groups were compared, a
Friedman rank sum test was performed. Survival
curves for time-dependent variables were assessed
with Kaplan-Meier estimates. The results were con-
sidered signiﬁcant when 2-sided p values were <0.05.
All analyses were performed with the SPSS statistical
software package (version 19, SPSS Inc., Chicago,
Illinois).FIGURE 1 THV Implantation in the Mitral Position: Example of a
Valve-in-Ring Procedure
(A) Following transseptal puncture, the mitral ring is crossed with a Judkins right diag-
nostic catheter or a balloon ﬂoatation catheter, and a stiff wire is placed at the apex of the
left ventricle. (B) The transcatheter heart valve (THV) is advanced through the atrial
septum, placed within the mitral ring, and inﬂated using rapid ventricular pacing.
(C,D) Final results after mitral valve-in-ring implantation using ﬂuoroscopy. (E,F)
Post-implantation computed tomography 3-dimensional reconstruction after mitral
valve-in-ring implantation.RESULTS
BASELINE CHARACTERISTICS. Transfemoral im-
plantation of a THV in the mitral position was
attempted in 17 patients. Patients’ characteristics are
shown in Table 1.
The type of index surgery was mitral valve
replacement in 6 patients and mitral valve repair in 11
patients.
Mean age was 61  24 years (range 18 to 90 years).
The majority of patients were female (n ¼ 13, 76.5%).
All patients were highly symptomatic; 12 patients
(70.6%) were in New York Heart Association (NYHA)
class III, and 5 (29.4%) were in class IV. Mean logistic
EuroSCORE (European System for Cardiac Operative
Risk Evaluation) was 37  29%, mean EuroSCORE II
was 20  22%, and mean Society of Thoracic Surgeons
score was 18  22%. This population included 3 young
women with a desire for pregnancy and at high sur-
gical risk due to major pulmonary hypertension and
severe right ventricular dysfunction for 2 of them and
a coronary bypass just beneath the sternum for the
third.
The mean delay since the last surgery was 8.1  4.7
years. The mode of valve failure was stenosis in the
majority of patients (n ¼ 11, 64.7%), whereas 5 pa-
tients (29.4%) presented moderate to severe regurgi-
tation and 1 patient (5.9%) had a combination of both
mechanisms.
Three MVIVI were performed as rescue inter-
ventions in 3 patients with cardiogenic shock, 2 under
extracorporeal membrane oxygenation or support: 1patient with severe stenosis of a BP that had been
implanted 10 years previously (Patient #1); 1 patient
with a residual severe prosthetic regurgitation 2 days
after surgical mitral valve replacement (Patient #2);
and 1 patient with severe prosthetic stenosis 23 days
following surgical mitral valve replacement (Patient
#5). Types of failing BP and RA, along with implanted
THV size, are shown in Table 2.
TABLE 1 Baseline and Periprocedural Characteristics
of the Population (N ¼ 17)
Pre-procedure
Age, yrs 60.7  23.9
Female 13 (76.5)
Chronic obstructive pulmonary disease 4 (23.5)
Chest radiation therapy 4 (23.5)
Hypertension 9 (52.9)
Diabetes 4 (23.5)
Atrial ﬁbrillation 12 (70.6)
NYHA functional class
III 12 (70.6)
IV 5 (29.4)
STS score, % 18.3  21.8
Logistic EuroSCORE, % 37.0  28.7
EuroSCORE II, % 20.1  22.3
Echocardiography
Mitral valve area, cm2 1.0  0.6
Mean mitral gradient, mm Hg 12.1  5.5
LVEF, % 55.3  12.0
Systolic PAP, mm Hg 57.7  11.3
Mitral regurgitation
0 5 (29.4)
1 4 (23.5)
2 3 (17.7)
3 1 (5.9)
4 4 (23.5)
Creatinine clearance, ml/min 65.1  38.9
Hemoglobin, g/dl 11.6  1.8
NT-proBNP, ng/l 1,791.9  1,322.3
Post-procedure echocardiography at day 7
Mitral valve area, cm2 2.2  1.1
Mean mitral gradient, mm Hg 8.0  2.5
LVEF, % 55.5  12.3
Systolic PAP, mm Hg 47.9  14.4
Mitral regurgitation
0 4 (25)
1 7 (44)
2 4 (25)
3 1 (6)
Values are mean  SD or n (%).
EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation;
LVEF ¼ left ventricular ejection fraction; NT-proBNP ¼ N-terminal pro–B-type
natriuretic peptide; NYHA ¼ New York Heart Association; PAP ¼ pulmonary artery
pressure; STS ¼ Society of Thoracic Surgeons.
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86Rings were semirigid in 8 cases (Carpentier
Edwards Physio, Edwards Lifesciences), rigid in 1 case
(Carpentier Edwards Classic, Edwards Lifesciences),
and ﬂexible in 2 cases (Duran AnCore, Medtronic,
Minneapolis, Minnesota).
Among the 12 patients with stenotic mitral failure,
mean transmitral gradient at baseline was 13.8 
4.1 mm Hg.
PROCEDURES. A Sapien XT valve was implanted in
16 patients (94%). Failure to implant a THV occurredduring a rescue procedure complicated by death,
which likely resulted from rupture of the inferior
vena cava following maneuvers to position the THV
within a failing BP that was implanted obliquely in a
supra-annular atrial position (Patient #2).
A 26-mm Sapien XT valve was implanted in 12
patients (71%), whereas 2 patients were treated with
a 23-mm and 2 patients with a 29-mm Sapien XT
valve (Table 2). The size of the valve was chosen by
an integrative approach taking into account TEE, CT,
and ﬂuoroscopic measurements (Figures 2A and 2D,
2B and 2E, and 2C and 2F, respectively), with ﬂuo-
roscopy usually providing the largest and TEE the
smallest diameters. Mean mitral annulus size was
indeed 21.4  2.0 mm for echographic evaluation,
23.7  2.2 mm for CT evaluation, and 25.2  2.1 mm
for ﬂuoroscopic evaluation (p < 0.001) (Figure 2G).
Valve implantation was performed under rapid
ventricular pacing in all but 1 patient in cardio-
genic shock, who had no more venous access avail-
able, in whom it was made using maximal
ventricular unloading from an extracorporeal mem-
brane oxygenator.
Procedural success was achieved in 14 in-
terventions (82%). The 3 procedural failures included
the previously mentioned death, 1 THV migration,
and a moderate paraprosthetic mitral regurgitation.
There was no conversion to open heart surgery.
The THV migration occurred during a rescue MVIVI
(Patient #1) and was related to undersizing. We used a
26-mm Sapien XT, which was the largest valve
available on a NovaFlex catheter at that time and
deemed to be the only possible option in this patient
in shock and heparin-induced thrombocytopenia (21).
Following migration of a ﬁrst THV, a second 26-mm
THV was successfully implanted within the BP with
the addition of an extra milliliter of contrast medium
in the inﬂator. Due to the prohibitive risk of surgery,
the migrated valve was left in the left atrium and
subsequently became entrapped in the left atrial
appendage, with an uneventful in-hospital outcome.
The moderate paravalvular regurgitation occurred
after mitral valve-in-ring implantation of a 26-mm
Sapien XT within a 27-mm Duran AnCore ring (Med-
tronic). The patient required surgical mitral valve
replacement 6 months after discharge for heart fail-
ure and severe pulmonary hypertension.
There was 1 minor vascular complication during an
emergency procedure requiring an unplanned surgi-
cal access closure following laceration of the femoral
vein after forced retrieval of a nonimplanted valve.
The other in-hospital complication was a tempo-
rary renal replacement therapy after a rescue
procedure.
TABLE 2 Characteristics of the BP and Annuloplasty Rings
Patient #
Type of Failed
MV Surgery Failure Mode Failing BP/R Type
BP/R Label
Size
Implanted
THV Size
1* Replacement Stenosis CE Perimount Magna BP 31 26
2* Replacement Regurgitation CE Perimount Magna BP 27 NA
3 Replacement Stenosis CE Porcine BP 31 26
4 Replacement Stenosis CE Perimount Magna BP 27 26
5* Replacement Stenosis CE Perimount Magna BP 31 29
6 Replacement Stenosis CE Perimount Magna BP 29 26
7 Repair Combined CE Physio R 28 26
8 Repair Stenosis CE Physio R 28 26
9 Repair Regurgitation CE Classic (mitral) R 30 26
10 Repair Regurgitation CE Physio R 26 26
11 Repair Stenosis CE Physio R 28 23
12 Repair Stenosis Medtronic Duran AnCore R 27 26
13 Repair Regurgitation Medtronic Duran AnCore R 31 26
14 Repair Stenosis CE Physio R 32 26
15 Repair Stenosis CE Physio R 30 26
16 Repair Stenosis CE Physio R 26 23
17 Repair Regurgitation CE Physio R 36 29
*Rescue procedures performed in patients in shock.
BP ¼ bioprosthesis, CE ¼ Carpentier-Edwards; MV ¼ mitral valve; NA ¼ not available; R ¼ ring;
THV ¼ transcatheter heart valve.
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87On the echocardiographic evaluation performed at
day 7, mean transvalvular gradient decreased from
13.8  4.1 mm Hg to 8.1  2.6 mm Hg (p < 0.003)
among the patients with mitral stenotic failure
(Figure 3). Three patients had a “signiﬁcant” residual
stenosis (mean gradient >10 mm Hg), according to the
American Society of Echocardiography (20). Further-
more, there was no residual regurgitation in 4 cases,
whereas it was quantiﬁed as trace in 7 cases, mild in 4
cases, and moderate in 1 case (Figure 4). Left ven-
tricular outﬂow tract obstruction occurred in 3 cases
after mitral valve-in-ring implantation, with maximal
gradients of 25, 46, and 49 mm Hg at discharge. There
was no clinical impact of these left ventricular
outﬂow tract obstructions with no congestive heart
failure during hospitalization, the 3 patients being in
NYHA class II. No patient needed reintervention due
to left ventricular outﬂow tract obstruction. Further-
more, the maximal gradients decreased to 10, 8, and
15 mm Hg, respectively, on echocardiographic control
examinations.
30-DAY OUTCOME. Kaplan-Meier 30-day survival
rates were 94.1% in the overall population and 100%
in patients who underwent an elective procedure.
The events that occurred during this period are
detailed in Table 3. One instance of severe bleeding
occurred as a possible inferior vena cava rupture in
the previously described patient who underwent a
rescue procedure. No patients experienced major
stroke or severe bleeding when they beneﬁted from
an elective procedure.
MIDTERM OUTCOME. Mean follow-up was 22.4  2.8
months. There were 4 deaths during follow-up: 1
patient died after 75 days from a cerebral tumor that
was unknown at the time of the procedure (Patient
#3); 2 patients had sudden death at 158 and 373 days
(Patients #1 and #9). The fourth patient underwent
successful transcatheter aortic valve replacement
371 days after mitral valve-in-ring implantation for
progression of aortic stenosis and died from an un-
known cause 253 days after the reintervention (Patient
#7). These 4 patients were at extremely high surgical
risk (mean Society of Thoracic Surgeons score ¼ 32%),
and the patient who suffered sudden death at 158 days
had beneﬁted from a rescue procedure. All 4 patients
were in NYHA class II, and they had no prosthesis
dysfunction at the last follow-up before death
occurred. Furthermore, 1 patient underwent mitral
valve replacement and tricuspid RA after 195 days
because of heart failure, persistent pulmonary
hypertension, and moderate mitral regurgitation.
Kaplan-Meier survival rates at 1-year and 18-month
follow-up, respectively, were 80  11% and 68  14%in the overall population and 91  9% and 78  14% in
the 14 patients who underwent an elective procedure
(Figure 5).
At the latest follow-up, there was an improvement
in functional class compared with baseline, with 13
patients in NYHA class #II, whereas 3 patients were in
class III due to radiation-induced cardiomyopathy
(n ¼ 1) or irreversible right ventricular dysfunction
(n ¼ 2).
DISCUSSION
The major ﬁnding from the present study is that
transfemoral implantation of Sapien XT valves in
failed mitral BP and RA is feasible in highly selected
patients with an acceptable rate of procedural success
and is associated with favorable early and midterm
outcomes.
POPULATION. It should be stressed that the proce-
dure was performed in patients at high surgical risk,
due to their age (oldest patient was 90 years), their
comorbidities, and the advanced stage of their heart
valve disease. Indeed, all patients were in NYHA class
III or IV before the procedure, and several of them
had undergone previous multiple open heart sur-
geries. In addition, of the 17 patients who underwent
the procedure, 3 patients were in cardiogenic shock
and underwent rescue interventions (2 under circu-
latory assistance).
FIGURE 2 Measurements of the Inner Diameter of a BP and an Annuloplasty Ring by Fluoroscopy, CT, and 3D TEE
Shown are measurements of the inner diameter of a bioprosthesis (BP) (A to C) and an annuloplasty ring (D to F) as determined by ﬂuoroscopy
(A, D), computed tomography (CT) (B, E), and 3-dimensional (3D) transesophageal echocardiography (TEE) (C, F). (G) Respective mean mitral
annular diameters assessed by ﬂuoroscopy, CT, and TEE. A Friedman rank sum test was performed with p < 0.05 considered signiﬁcant.
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88PROCEDURAL APPROACH. The ﬁrst 2 cases of MVIVI
were performed by Webb et al. (6) via a transseptal
and a transatrial approach. However, these routes
were abandoned after unfavorable outcomes due to
difﬁculties in achieving a coaxial alignment of the
THV and the mitral prosthesis. Thereafter, the team
successfully performed all MVIVI via a transapical
approach (10), which has been adopted as the default
route by most other centers performing THV im-
plantation in the mitral position (9,11–13). Neverthe-
less, our results, associated with reports from other
groups (8,22), suggest that THV implantation in themitral position may be alternatively performed using
the transseptal approach. Although more challenging
to obtain than with the transapical route, sufﬁcient
coaxiality and stabilization were achieved here using
the combination of a TEE-guided transseptal punc-
ture, the ﬂexing properties of the NovaFlex catheter,
and slow balloon inﬂation allowing adjustment dur-
ing THV implantation.
The transseptal approach, which has the advantage
of being less invasive than the transapical route, may
therefore have a signiﬁcant impact on the outcome.
In addition, it may allow the procedure to be
FIGURE 3 Mean Transmitral Gradient Before and After THV
Implantation in the Mitral Position Among the 12 Patients
With Mitral Stenotic Failure
A Wilcoxon matched test was performed with p < 0.05 consid-
ered signiﬁcant. THV ¼ transcatheter heart valve.
TABLE 3 Clinical Events at 30 Days
Overall Population
(n ¼ 17)
Elective Procedures
(n ¼ 14)
Death 1 (5.9) 0 (0)
Myocardial infarction 0 0
Major stroke 0 0
Minor stroke 0 0
TIA 0 0
Major bleeding 1 (5.9) 0
Minor bleeding 0 0
Reintervention 0 0
PM implantation 0 0
Severe vascular complication 1 (5.9) 0
Infectious complication 0 0
Values are n (%).
PM ¼ pacemaker; TIA ¼ transient ischemic attack.
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89performed under conscious sedation. In the largest
published series of transapical MVIVI, Cheung et al.
(10) reported a 26% rate of major bleeding in elective
procedures only, whereas in a smaller series of 6 pa-
tients treated with the same approach, 1 patient died
after the procedure due to acute bleeding from the
apical wound, and another required rethoracotomy
due to hemothorax (12). In the present series, 1 fatal
instance of bleeding occurred during a rescue
procedure (the previously described possible rupture
of the inferior vena cava). There was no other
severe bleeding during the hospital course and thus
no bleeding for the elective procedures. When
comparing our results to Cheung’s series, the 30-day
survival rates were both 100% in elective patients.
Thus, our results suggest that transfemoralFIGURE 4 Graded Mitral Regurgitation Before and After
THV Implantation in 17 Patients
Post-procedural mitral regurgitation was not available for
Patient #2, who died during the procedure (n ¼ 16 for post-
procedural assessment). THV ¼ transcatheter heart valve.transseptal approach may be a valid alternative to the
transapical approach in centers beneﬁting from a
large experience in transseptal interventions.
Recently, Cullen et al. (7) reported the combination
of transseptal and transapical approaches in failed
mitral and tricuspid bioprostheses by using the
Melody valve (Medtronic). Although such a strategy is
likely to improve coaxiality and stability during THV
delivery, the use of a left ventricular puncture also
increases the complexity and risk of the procedure, as
complication rates of 7% to 30% following transapical
puncture have been reported (23,24). Accordingly,
although all 9 patients successfully underwent im-
plantation of the Melody valve within a failed mitral
BP, 2 patients (22%) presented a left hemothorax.
In the present series, the only procedural failure
that could be related to the lack of support concerns
Patient #2, in whom emergency MVIVI was attemp-
ted for a BP implanted obliquely in a supra-annular
atrial position due to massive mitral annulus calci-
ﬁcations. Crossing of the mitral BP with the THV was
impossible and further maneuvers to advance the
THV likely led to rupture of the inferior vena cava
and death. It is possible that a transapical approach
would have allowed positioning of the THV within
the BP, but this treatment option had been ruled
out upfront by the heart team due to the patient’s
condition.
MITRAL PROSTHESIS SIZE EVALUATION. An impor-
tant point of discussion relates to sizing issues,
particularly for annuloplasty rings, which have an
oval shape and various degrees of rigidity. In the
absence of deﬁnite recommendations, the choice re-
lies on an integrative approach taking into account
the 3 available measurement methods (TEE, CT,
ﬂuoroscopy). Despite the small sample size,
FIGURE 5 Survival of the Overall Population (n ¼ 17) and of the Patients Who
Underwent an Elective Procedure (n ¼ 14)
Survival at 30 days, 1 year, and 18 months after transcatheter heart valve implantation in
the mitral position.
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90differences in mitral annulus diameters according to
the method used highlight the need not to rely on a
single technique. In particular for stenosed rings,
transcatheter prosthesis sizing should take into ac-
count not only the inner ring diameter but also the
adjacent valvular tissue, which is not detected by CT
scanner or ﬂuoroscopy. The measurement of the
diameter of the inﬂated balloon during pre-dilation
may help to assess the amount of valvular tissue
and avoid implanting a too large valve.
MIDTERM RESULTS. The midterm results of elective
procedures are good with 91% and 78% survival at 1
year and 18 months, respectively, despite the high-
risk proﬁle of this selected population. Deaths were
cardiac-related in 2 of 3 patients in this population
and consisted of sudden death. The results of the
procedure were good whatever the mode of valvefailure (stenosis or regurgitation). Moreover, a large
majority of patients experienced functional im-
provement with 12 out of 14 patients (86%) in
NYHA class #2 at the latest follow-up. As well as the
safety of the elective procedures, with no severe
complication or death in the present series, we report
encouraging midterm results.
STUDY LIMITATIONS. This is a single-center, obser-
vational study in a small cohort of highly selected
patients, without comparison to surgical manage-
ment, which is considered the treatment of choice in
this setting. However, a single-center series ensures
homogeneity in patient selection and the perfor-
mance of the technique, which is of particular
importance in innovative procedures.
CONCLUSIONS
This single-center series suggests that transfemoral
THV implantation for degenerated mitral surgical
bioprosthesis, or repair using annuloplasty rings, is
feasible and may improve early hemodynamic and
functional status in selected patients, in particular
those at high risk for surgery. The various reported
approaches imply the absence of a consensus on the
best strategy for these complex procedures at the
present time. Larger series with long-term follow-up
are needed to assess the potential role of this tech-
nique. Moreover, reporting of all the experience with
such procedures is essential to improve results and
outcomes and will certainly be useful for future
mitral transcatheter valve therapies with dedicated
devices.
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